Exagen Inc. (NASDAQ:XGN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $9.88.
XGN has been the subject of a number of research reports. B. Riley Financial began coverage on Exagen in a research report on Friday, September 11th. They set a “buy” rating and a $12.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. TD Cowen boosted their target price on shares of Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Canaccord Genuity Group decreased their target price on shares of Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, BTIG Research reaffirmed a “buy” rating and set a $9.00 price target on shares of Exagen in a report on Wednesday.
View Our Latest Research Report on Exagen
Exagen Trading Down 12.3%
Shares of NASDAQ:XGN opened at $4.41 on Tuesday. The business has a fifty day simple moving average of $7.78 and a 200-day simple moving average of $5.13. Exagen has a 52 week low of $2.59 and a 52 week high of $9.73. The company has a quick ratio of 3.18, a current ratio of 3.46 and a debt-to-equity ratio of 1.73.
Exagen (NASDAQ:XGN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%. The business had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.34 million. On average, sell-side analysts predict that Exagen will post -0.69 EPS for the current year.
Insider Transactions at Exagen
In other news, CEO John Aballi sold 34,294 shares of Exagen stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the completion of the transaction, the chief executive officer directly owned 805,540 shares of the company’s stock, valued at approximately $6,339,599.80. The trade was a 4.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Jorey Chernett purchased 71,315 shares of the stock in a transaction dated Wednesday, November 11th. The shares were purchased at an average price of $5.23 per share, with a total value of $372,977.45. Following the transaction, the insider directly owned 2,696,940 shares of the company’s stock, valued at approximately $14,104,996.20. The trade was a 2.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 100,900 shares of company stock valued at $568,660 in the last three months. 10.40% of the stock is currently owned by company insiders.
Institutional Trading of Exagen
Large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LP acquired a new position in Exagen during the 2nd quarter worth $52,000. Penbrook Management LLC acquired a new stake in Exagen in the third quarter worth about $92,000. Calamos Advisors LLC bought a new position in Exagen in the 3rd quarter valued at about $94,000. Bank of New York Mellon Corp bought a new position in Exagen in the 2nd quarter valued at about $97,000. Finally, Dimensional Fund Advisors LP grew its position in Exagen by 137.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 62,571 shares of the company’s stock valued at $188,000 after buying an additional 36,213 shares in the last quarter. 75.25% of the stock is currently owned by institutional investors and hedge funds.
About Exagen
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
See Also
- Five stocks we like better than Exagen
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
